Intravacc, a provider of translational research and development of vaccines for infectious diseases and therapeutics, said the Chinese National Medical Products Administration (NMPA) formally known as the Chinese FDA, granted Sinovac Biotech market authorization for its Sabin-IPV (sIPV) inactivated polio vaccine, developed by Intravacc and out-licensed to Sinovac. This multivalent polio vaccine was developed by Intravacc for the purpose of providing low and middle-income countries with the oppor...